Recruiting Experienced Chief Technology Officer Pinetree Therapeutics

Antibody Engineering, Platform Technology & CMC

Location:

Cambridge, MA (on-site)

Reports to:

Chief Executive Officer (CEO)

Start Date:

Immediate

Pinetree Therapeutics is a rapidly growing biotechnology company developing next-

generation multispecific antibody therapies for targeted protein degradation in oncology

and immune modulation. Our proprietary AbReptor™ platform is a first-in-class

extracellular targeted protein degradation (eTPD) technology that uses bispecific and

multispecific antibodies to redirect disease-driving cell-surface and extracellular proteins

to lysosomal degradation, going beyond inhibition to remove the disease driver itself,

overcoming drug resistance and disease recurrence.

Our lead program, EGFR AbReptor™ (PTX-299), is licensed to AstraZeneca and

advancing toward first-in-human studies, with a growing wholly-owned pipeline

spanning c-MET, FGFR2, and additional targets, plus platform extensions into degrader-

antibody and antibody-drug conjugates (DuoDACtyl™ / dADC) and inflammation &

immunology. With research operations in Cambridge, MA and a clinical and preclinical

site in South Korea, we are a lean, hands-on, science-driven organization translating

innovative discovery concepts into first-in-class clinical candidates for patients with

“hard-to-treat” cancers and immune disorders.

We are seeking a seasoned biotech leader to serve as Chief Technology Officer (CTO),

the senior-most technical authority for antibody engineering, the AbReptor™ platform,

and CMC. Reporting to the CEO, the CTO will own the scientific and technical direction

of the platform and all antibody engineering and molecule development from discovery

through candidate nomination and IND-enabling readiness, leading Pinetree’s

established team of antibody engineering Directors and Principal Scientists while

working alongside the company’s scientific, clinical, and business leadership.

The ideal candidate is an accomplished antibody engineer and drug developer with

deep, hands-on expertise in multispecific antibody and antibody-fusion construct design,

and a proven record of advancing biologics from concept into the clinic. This is an

active, hands‑on technical leadership role: you will be the company’s definitive decision-

maker on antibody design and engineering, drive the hardest molecular design,

develop ability, and CMC decisions, and expand the platform into new modalities. The

successful candidate will be authoritative and self‑sufficient enough to independently

own the antibody engineering function and set molecular design direction across the

portfolio, while elevating an already-strong engineering team.

• Own the long-term scientific and technical vision for the AbReptor™ eTPD platform, ensuring Pinetree sustains its differentiation and first-in-class position in antibody-based
• Drive expansion of the platform into new formats and modalities, including next- generation multispecific degraders with tumor-microenvironment modulation, degrader- antibody conjugates (DAC / DuoDACtyl™), and degrading ADCs (dADC).
• Translate platform capabilities into a prioritized, differentiated portfolio of programs; contribute to target selection, program prioritization, timelines, and go/no-go decisions.
• Serve as Pinetree’s senior-most authority on antibody engineering, owning molecular design strategy and the final technical decisions across the multispecific degrader
• Provide expert, hands‑on leadership across multispecific antibody and antibody‑fusion construct design, including format selection, epitope and affinity tuning, valency, and geometry optimization, to achieve potent, selective degradation with a desirable safety profile.
• Direct protein engineering and molecular design from concept through lead optimization, embedding develop ability, manufacturability, and safety considerations early (“develop ability by design”).
• Be the definitive technical voice on the most challenging engineering and molecular characterization problems, guiding structure‑activity analysis and troubleshooting across programs.
• Lead the progression of antibody candidates from discovery through lead…